As the model tumor linking genomic disorders to cancer therapy, ctDNA analysis of non‐small cell lung cancer (NSCLC) have paved the road for the Cobas EGFR mutation Test v2 (Roche Diagnostics), the first ctDNA‐based companion diagnostic test to be approved by US FDA and the European Medicines Agency.69, 70. Here, EGFR is linked to non-small cell lung carcinoma.